Download PDF
Thromb Haemost 1994; 71(05): 692-697
DOI: 10.1055/s-0038-1642506
Review Article
Schattauer GmbH Stuttgart

Haemostatic Abnormalities Persist Despite Glycaemic Improvement by Insulin Therapy in Lean Type 2 Diabetic Patients

Paul Knöbl
1   The Dept. Med. II, University of Vienna, Vienna, Austria
,
Guntram Schernthaner
2   The Dept. Med. I, Rudolfstiftung Hospital, Vienna, Austria
,
Christoph Schnack
2   The Dept. Med. I, Rudolfstiftung Hospital, Vienna, Austria
,
Peter Pietschmann
1   The Dept. Med. II, University of Vienna, Vienna, Austria
,
Sylvia Proidl
1   The Dept. Med. II, University of Vienna, Vienna, Austria
,
Rudolf Prager
1   The Dept. Med. II, University of Vienna, Vienna, Austria
,
Thomas Vukovich
1   The Dept. Med. II, University of Vienna, Vienna, Austria
› Author Affiliations
Further Information

Publication History

Received: 14 May 1993

Accepted after revision 16 February 1993

Publication Date:
26 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Diabetes mellitus is associated with disturbances of the haemostatic system, which might contribute to the development of diabetic vascular disease. We investigated the effect of metabolic improvement by insulin therapy on the haemostatic system in 61 patients with type 2 diabetes mellitus and secondaxy sulfunyluiea failure compared with 45 healthy control subjects matched for age, sex and BMI. Median age was 65, median diabetes duration 10 years. Median HbA1c (10%) and fructosamine (4.0 mM) levels were elevated before induction of therapy and decreased significantly within 6 months of insulin treatment to 7.5% and 3.0 mM, respectively (p <0.0001). Compared with control subjects, median plasma levels of fibrinogen (317 vs 286 mg/dl), coagulation factor VII activity (1.1 vs 0.89 U/1), von Willebrand factor (1.6 vs 1.3 U/1), D-dimer (105 vs 86 jug/1), protein C:Ag (1.24 vs 0.95 U/1), total protein S:Ag (1.15 vs 0.91 U/1), and antithrombin III activity (1.17 vs 1.08 U/1) were significantly elevated. Levels of free protein S were not different from control values. No significant decline of coagulation parameters could be recorded during insulin therapy. Patients with diabetic vasculopathy had higher levels of D-dimer than those without (133 vs 76 μg/1 before, 109 vs 88 μg/1 during therapy), whereas the other haemostatic parameters were not different. Our data indicate a significant activation of the coagulation system in diabetic patients with secondary failure to sulfonylurea drugs, with signs of a prethrombotic state and endothelial cell disturbance. Induction of insulin therapy results in a significant improvement of glycaemic and lipid metabolism, but the persisting enhanced activity state of the haemostatic system might contribute to the increased cardiovascular mortality of type 2 diabetic patients.

 

  • References

  • 1 Cciiellu A. Cuugululiun aclivuLion in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects. Diabctologia 1993; 36: 1119-25
    PubMedGoogle Scholar
  • 2 Kwaan HC. Changes in blood coagulation, platelet function and plasminogen plasmin system in diabetes. Diabetes 1992; 41 Suppl (Suppl. 02) 32-5
    CrossrefPubMedGoogle Scholar
  • 3 Schernthaner G, Vukovich T, Gisinger C. Anomalies de l’hemostase au cours du diabete sucre. Journ Annu Diabetol Hotel Dieu 1991; 91-107
    PubMedGoogle Scholar
  • 4 Knöbl P, Schnack C, Pietschmann P, Griesmacher A, Prager R, Müller M, Schernthaner G. Thrombogenic factors are related to urinary albumin excretion rate in Type 1 and Type 2 diabetic patients. Diabetologia 1993; 36: 1045-50
    CrossrefPubMedGoogle Scholar
  • 5 Lee P, Jenkins A, Bourke C, Santamaria J, Paton C, Janus E, Best J. Prothrombotic and antithrombotic factors are elevated in patients with Type 1 diabetes complicated by microalbuminuria. Diab Med 1993; 10: 122-8
    CrossrefPubMedGoogle Scholar
  • 6 Fuller JH, Keen H, Jarrett RJ, Orner T, Meade TW, Chakrabarti R, North WRS, Stirling Y. Haemostatic variables associated with diabetes and its complications. Brit Med J 1979; 2: 964-6
    CrossrefPubMedGoogle Scholar
  • 7 Kannel WB, D’Agostino RB, Wilson PW, Belanger AJ, Gagnon DR. Diabetes, fibrinogen and risk of cardiovascular disease: the Framingham experience. Am Heart J 1990; 120: 672-6
    CrossrefPubMedGoogle Scholar
  • 8 Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WRS, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; 2: 533-7
    CrossrefPubMedGoogle Scholar
  • 9 Morrish NH, Stavens LK, Head J, Fuller JH, Jarrett RJ, Keen H. A prospective study of mortality among middle-aged diabetic patients (the London cohort if the WHO Multinational Study of Vascular Disease in Diabetics) I: causes and death rates. Diabetologia 1990; 33: 538-41
    CrossrefPubMedGoogle Scholar
  • 10 Morrish NJ, Stavens LK, Head J, Fuller JH, Jarrett RJ, Keen H. A prospective study of mortality among middle-aged diabetic patients (the London cohort if the WHO Multinational Study of Vascular Disease in Diabetics) II: associated risk factors. Diabetologia 1990; 33: 542-8
    CrossrefPubMedGoogle Scholar
  • 11 Uusitupa MU, Niskanen LK, Siitonen O, Voutilainen E, Pyörälä K. 5 year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in noninsulin-dependent diabetic and nondiabetic subjects. Circulation 1990; 82: 27-36
    CrossrefPubMedGoogle Scholar
  • 12 Jensen T. Increased plasma concentration of von Willebrand factor in insulin dependent diabetics with incipient nephropathy. Brit Med J 1989; 298: 27-8
    PubMedGoogle Scholar
  • 13 Borkenstein MH, Muntean WE. Elevated factor VIII activity and factor VIII related antigen in diabetic children without vascular disease. Diabetes 1982; 31: 1006-9
    CrossrefPubMedGoogle Scholar
  • 14 Vukovich TC, Schemthaner G, Knobl PN, Hay U. The effect of nearnormoglycaemic control on plasma factor VIII/von Willebrand factor and fibrin degradation products in insulin dependent diabetic patients. J Clin Endocrinol Metab 1989; 69: 84-9
    CrossrefPubMedGoogle Scholar
  • 15 Vukovich T, Schemthaner G. Decreased protein C levels in patients with insulin dependent type 1 diabetes mellitus. Diabetes 1986; 35: 617-9
    CrossrefPubMedGoogle Scholar
  • 16 Vigano S, Mannucci PM, D’Angelo A, Gelfi C, Gensini GF, Rostagno C, Neri Serneri GG. Protein C Antigen is not an acute phase reactant and is often high in ischemic heart disease and diabetes. Thromb Haemost 1984; 52: 263-6
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Takahashi H, Tatewaki W, Wada K, Shibata A. Plasma protein S in disseminated intravascular coagulation, liver disease, collagen disease, diabetes mellitus, and under oral anticoagulant therapy. Clin Chim Acta 1989; 182: 195-208
    CrossrefPubMedGoogle Scholar
  • 18 Oida K, Takai H, Maeda H, Takahashi S, Tamai T, Nakai T, Miyabo S, Ishii H. Plasma thrombomodulin concentration in diabetes mellitus. Diab Res Clin Pract 1990; 10: 193-6
    CrossrefPubMedGoogle Scholar
  • 19 Tanaka A, Ishii H, Hiraishi S, Kazama M, Maezawa H. Increased thrombomodulin values in plasma of diabetic men with microangiopathy. Clin Chem 1991; 37/2: 269-72
    PubMedGoogle Scholar
  • 20 Takahashi H, Seiki I, Hanano M, Wada K, Niwano H, Seki Y, Shibata A. Circulating thrombomodulin as a novel endothelial cell marker: comparison of its behavior with von Willebrand factor and tissue-type plasminogen activator. Am J Hematol 1992; 41: 32-9
    CrossrefPubMedGoogle Scholar
  • 21 Gough SCL, Grant PJ. The fibrinolytic system in diabetes mellitus. Diab Med 1991; 8: 898-905
    CrossrefPubMedGoogle Scholar
  • 22 Van Wersch JW, Westerhuis LW, Venekamp WJ. Glycometabolic control and fibrinolysis in diabetic patients. Haemostasis 1990; 20: 241-50
    PubMedGoogle Scholar
  • 23 Speiser W, Speiser P, Minar E, Korninger C, Niessner H, Huber K, Schemthaner G, Ehringer H, Lechner K. Activation of coagulation and fibrinolysis in patients with arteriosclerosis. Thromb Res 1990; 59: 77-88
    CrossrefPubMedGoogle Scholar
  • 24 Marongiu F, Conti M, Mameli G, Sorano GG, Cossu E, Cilillo R, Balestrieri A. Is the imbalance between thrombin and plasmin activity in diabetes related to the behaviour of antiplasmin activity?. Thromb Res 1990; 58: 91-9
    CrossrefPubMedGoogle Scholar
  • 25 Garcia-Frade LJ, de la Calle H, Torrado MC, Lara JI, Cuellar L, Garcia Avello A. Hypofibrinolysis associated with vasculopathy in non insulin dependent diabetes mellitus. Thromb Res 1990; 59: 51-9
    CrossrefPubMedGoogle Scholar
  • 26 Takahashi H, Tsuda A, Tatewaki W, Wada K, Niwano H, Shibata A. Activation of blood coagulation and fibrinolysis in diabetes mellitus: evaluation by plasma levels of thrombin – antithrombin III complex and plasmin – alpha 2 plasmin inhibitor complex. Thromb Res 1989; 55: 727-35
    CrossrefPubMedGoogle Scholar
  • 27 Simonson DC. Hyperinsulinaemia and its sequelae. Horm Metab Res Suppl 1990; 22: 17-25
    PubMedGoogle Scholar
  • 28 Robertson DA, Hale PJ, Nattrass M. Macrovascular disease and hyperinsulinaemia. Baillieres Clin Endocrinol Metab 1988; 2: 407-24
    CrossrefPubMedGoogle Scholar
  • 29 Stolar MW. Atherosclerosis in diabetes: the role of hyperinsulinaemia. Metabolism 1988; 37 2 Suppl (Suppl. 01) 1-9
    PubMedGoogle Scholar
  • 30 Schemthaner G, Vukovich T, Knobl P, Hay U, Müller M. The effect of near normoglycaemic control on plasma levels of coagulation factor VII and the anticoagulants protein C and S in insulin dependent diabetic patients. Brit J Haematol 1989; 73: 356-9
    CrossrefPubMedGoogle Scholar
  • 31 Knobl PN, Fischer P, Kaliman JF, Vukovich TC. Plasma levels of protein C and protein S in patients with vasculopathy. Thromb Res 1987; 45: 857-63
    CrossrefPubMedGoogle Scholar
  • 32 Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol Leipzig 1957; 17: 237-40
    PubMedGoogle Scholar
  • 33 SAS Users Guide. SAS Institute, Statistical Analysis System. Cary, North Carolina: 1985. ISBN 0-917382-36-6
    Google Scholar
  • 34 Kudlacek S, Schemthaner G. The effect of insulin treatment on HbAlc, body weight and lipids in type 2 diabetic patients with secondary-failure to sulfonylureas. A five year follow-up study. Horm Metab Res 1992; 24: 455-500
    Article in Thieme ConnectPubMedGoogle Scholar
  • 35 Schmitz A, Ingerslev J. Haemostatic measurements in Type 2 (non-insulin-dependent) diabetic patients with microalbuminurea. Diabetic Med 1990; 7: 521-5
    CrossrefPubMedGoogle Scholar
  • 36 Jumming L, Vilcek J. Interleukin 6: a multifunctional cytokine regulating immune reactions and the acute phase protein response. Lab Invest 1988; 61: 588-602
    PubMedGoogle Scholar
  • 37 Hornsby WG, Boggess KA, Lyons TJ, Barnwell WH, Lazarchick J, Colwell JA. Haemostatic alterations with exercise conditioning in NIDDM. Diabetes Care 1990; 13: 87-92
    CrossrefPubMedGoogle Scholar
  • 38 Jennings AM, Ford I, Murdoch S, Greaves M, Preston FE, Ward JD. The Effects of Diet and Insulin Therapy on Coagulation Factor VII, Blood Viscosity, and Platelet Release Proteins in Diabetic Patients with Secondary Sulfonylurea Failure. Diab Med 1990; 8: 346-53
    PubMedGoogle Scholar
  • 39 Elkeles RS, Chakrabarti R, Vickers M, Stirling Y, Meade TW. Effect of treatment of hyperlipidaemia on haemostatic variables. Brit Med J 1980; 281: 973-4
    CrossrefPubMedGoogle Scholar
  • 40 Vukovich T, Proidl S, Knöbl P, Teufelsbauer H, Schnack C, Schemthaner G. The effect of insulin treatment on the balance between tissue plasminogen activator and plasminogen activator inhibitor-1 in type 2 diabetic patients. Thromb Haemost 1992; 68: 253-6
    Article in Thieme ConnectPubMedGoogle Scholar
  • 41 Sinzinger H, Virgolini I. Nuclear medicine and atherosclerosis. Europ J Nucl Med 1990; 17: 160-78
    PubMedGoogle Scholar